TICKERNERD
Menu
PAHCPAHCHealthcare · Drug Manufacturers - Specialty & Generic

PAHC Stock Forecast: Phibro Animal Health Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$36
+3.24% on the day

The 5 Wall Street analysts covering Phibro Animal Health Corp. hold a median 12-month price target of $44 — +21.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
89 / 100
Median analyst target
$44
Analysts covering
5
Total return, dividends reinvested
1W
+5.7%
1M
+7.3%
YTD
−2.3%
1Y
+16.5%
From 52W high
−38.9%
From 52W low
+27.7%
$28
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PAHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phibro Animal Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Growth
95
Quality
92
Volatility
89
Revisions
76
Momentum
53
Issuance
51
Size
40
Accruals
20

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (20): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PAHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60Oct 25Jan 26Apr 26Jul 26PAHCHigh $58Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
1 Buy3 Hold1 Sell
Low $35Median $44High $58

The green dot is the last close — the median target sits +21.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026CitigroupMaintainsNeutral$62 → $44
14 May 2026CitigroupMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
7 Nov 2025JP MorganMaintainsOverweight—
29 Aug 2025B of A SecuritiesMaintainsUnderperform—
7 July 2025JP MorganUpgradeOverweight—
25 June 2025Morgan StanleyMaintainsEqual-Weight—
8 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Feb 2025BarclaysMaintainsUnderweight—
17 Dec 2024Morgan StanleyMaintainsEqual-Weight—
12 Nov 2024BarclaysMaintainsUnderweight—
10 Sept 2024JP MorganInitiatesNeutral—
30 Aug 2024B of A SecuritiesMaintainsUnderperform—
10 May 2024BarclaysMaintainsUnderweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
1 Sept 2023Roth MKMReiteratesBuy—
31 Aug 2023Morgan StanleyMaintainsEqual-Weight—
29 Aug 2023Roth MKMReiteratesBuy—
27 July 2023Morgan StanleyReiteratesEqual-Weight—
4 May 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PAHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PAHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Phibro Animal Health Corp. (PAHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.6×

Cheaper than 46% of US stocks

Price / sales
1.0×

Cheaper than 71% of US stocks

Price / book
4.1×

Cheaper than 27% of US stocks

EV / EBITDA
9.3×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
10.3%

Higher than 53% of US stocks

Earnings growth (YoY)
15.1%

Higher than 53% of US stocks

Gross margin
32.8%

Higher than 39% of US stocks

Operating margin
12.6%

Higher than 68% of US stocks

Net margin
6.3%

Higher than 63% of US stocks

Returns & dividend
Return on equity
30.3%

Higher than 88% of US stocks

Return on assets
8.4%

Higher than 89% of US stocks

Dividend yield
1.3%

Higher than 32% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PAHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PAHCPhibro Animal Health Corp.$1.5B
89
HROWHarrow, Inc.$1.5B
49
ANIPANI Pharmaceuticals, Inc.$1.7B
95
ALVOAlvotech$1.7B
26
ETONEton Pharmaceuticals, Inc.$1.8B
99
PRGOPerrigo Co. Plc$2.0B
69
TRLVTrulieve Cannabis Corp.$2.1B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phibro Animal Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PAHC news & analysis

Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Zacks Investment Research · 21 Aug 2026neutral

Zacks Research previews Phibro Animal Health Corp.'s (PAHC) fiscal Q4 earnings for the quarter ended June 2026. In addition to Wall Street's top- and bottom-line estimates, the article reviews projections for key company metrics to help investors assess how the company may have performed.

Why it matters — The piece gives PAHC watchers a look at expected performance across key metrics ahead of the earnings release, offering a framework for evaluating the company's quarterly results.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results

Business Wire · 19 Aug 2026neutral

Phibro Animal Health Corporation announced it will report fourth quarter and fiscal year 2026 financial results after the market closes on Wednesday, August 26, 2026, and will host a conference call and webcast the following morning at 9:00 AM Eastern Time, accessible via its investor website. The announcement provides the date and logistics for the upcoming earnings call.

Why it matters — PAHC watchers will want to know when the company will release its fiscal year results and how to tune in for management's discussion of the quarter and full year.

Should You Continue to Retain PAHC Stock in Your Portfolio?

Zacks Investment Research · 19 Aug 2026neutral

Zacks Investment Research published an analysis of Phibro Animal Health, noting that the company's Animal Health segment growth and global reach support its outlook, while Brazil's antimicrobial transition and trade risks cloud near-term prospects. The report discusses whether investors should continue to retain PAHC stock in their portfolios.

Why it matters — PAHC watchers would care because the analysis weighs the company's growth strengths against near-term headwinds from Brazil's antimicrobial transition and trade risks.

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Zacks Investment Research · 7 Aug 2026neutral

Zacks Investment Research published an article exploring whether Phibro Animal Health (PAHC) may be undervalued by investors, focusing on the company's standing within value, growth, and momentum trends.

Why it matters — The article signals that PAHC is being evaluated through a valuation lens, which could influence how investors perceive the stock's current market position.

Phibro Animal Health Corporation Declares Quarterly Dividend

Business Wire · 28 July 2026positive

Phibro Animal Health Corporation's Board of Directors declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock, payable on September 23, 2026, to stockholders of record as of September 2, 2026.

Why it matters — The declaration of a quarterly dividend signals the company's ongoing commitment to returning value to shareholders.

FAQ

Frequently asked questions about PAHC stock

What is the PAHC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Phibro Animal Health Corp. have a median 12-month price target of $44, with estimates ranging from $35 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAHC stock a buy right now?

Of the 5 analysts covering Phibro Animal Health Corp., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Phibro Animal Health Corp. 89 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAHC?

As at 22 Aug 2026, Phibro Animal Health Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will PAHC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +21.1% from the last close, and Ticker Nerd's factor model ranks Phibro Animal Health Corp. 89 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAHC stock forecast for 2030?

No analyst covering Phibro Animal Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $58 over the next 12 months.

How has PAHC stock performed over the past year?

Phibro Animal Health Corp. returned +16.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phibro Animal Health Corp. do?

Phibro Animal Health Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of a wide range of animal health and mineral nutrition solutions. Primarily, the company serves the livestock and poultry sectors by providing medications and vaccines that enhance the health and productivity of animals.

What is the latest news on PAHC?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates". Zacks Research previews Phibro Animal Health Corp.'s (PAHC) fiscal Q4 earnings for the quarter ended June 2026. In addition to Wall Street's top- and bottom-line estimates, the article reviews projections for key company metrics to help investors assess how the company may have performed.

Company

About Phibro Animal Health Corp.

Phibro Animal Health Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of a wide range of animal health and mineral nutrition solutions. Primarily, the company serves the livestock and poultry sectors by providing medications and vaccines that enhance the health and productivity of animals. Phibro's extensive product portfolio includes antimicrobials, vaccines, mineral premixes, and specialty products developed to support the animal agriculture industry. The company plays a significant role in improving animal welfare as well as animal-derived food safety, thus contributing directly to the agricultural supply chain. Established in 1946 and headquartered in Teaneck, New Jersey, Phibro operates globally, catering to the needs of veterinarians, farmers, and feed producers across diverse markets. Its products are pivotal in addressing challenges such as outbreaks of diseases among livestock, thereby helping to ensure the profitability and sustainability of animal farming operations worldwide.

CEO Mr. Jack Clifford Bendheim · 2,475 employees · United States · https://www.pahc.com